For the Inventor, By the Inventor

Enter assignee name

Dainippon Sumitomo Pharma Co., Ltd.

USPTO Granted Patents = 140

CIPO Patents = 9

EPO Patents = 37

Trademarks = 8

Forward Citations = 853

Loading Chart...

Loading Chart...

257 inventors (with patents filed for the assignee):

Yoshiaki Isobe (8 out of 28 patents)

Ayumu Kurimoto (7 out of 9 patents)

Stephen Thom (7 out of 60 patents)

4. Tomohiro Toyoda (6 out of 11 patents)

5. Masashi Gotoh (6 out of 8 patents)

6. Thomas McInally (6 out of 26 patents)

7. Roger Victor Bonnert (6 out of 46 patents)

8. Takahiro Ochiya (5 out of 44 patents)

9. Hidefumi Yoshinaga (5 out of 18 patents)

10. Shinya Yamanaka (5 out of 40 patents)

11. Izumu Saito (5 out of 20 patents)

12. Haruo Sugiyama (4 out of 68 patents)

13. Nobuhisa Fukuda (4 out of 5 patents)

14. Haruhisa Ogita (4 out of 9 patents)

15. Thomas Mcinally (4 out of 5 patents)

Core Competencies:

Alzheimer's Disease

Adenine Compound

Oral Disintegrating Tablet

Cancer Immunotherapy

Benzyl Piperidine Compound

Immuno-Modulating Properties

Pharmaceutical Composition

Bicyclic Heterocyclic Compound

Nucleic Acid Transfer

Human Monoclonal Antibody

Therapeutic Agent for Senile Dementia

Recombinant Adenovirus Vector

140 patents: Sort by Forward Citations

1. 10393757 - Diagnostic drug and diagnostic method for Alzheimer's disease (2019-08-27),

2. 8865896 - Method for preparing adenine compound (2014-10-21),

3. 8809383 - Pyrazole compound (2014-08-19),

4. 8785406 - Stabilized and lyophilized formulation of anthracycline compounds (2014-07-22),

5. 8778970 - Benzyl piperidine compound (2014-07-15),

6. 8778392 - Oral disintegrating tablet (2014-07-15),

7. 8765939 - Pyrimidline derivatives having immune modulating properties that act via TLR7 for the treatment of viral or allergic diseases and cancers (2014-07-01),

8. 8765786 - 1-substituted indazole derivative (2014-07-01),

9. 8742091 - Method of promoting nucleic acid transfer (2014-06-03),

10. 8735406 - 8-oxodihydropurine derivative (2014-05-27),

11. 8735397 - Method for treating schizophrenia and related diseases (2014-05-27),

12. 8729085 - Pharmaceutical composition (2014-05-20),

13. 8673907 - Pharmaceutically acceptable salts of methyl (3-{ [[3-(6-amino- 2-butoxy-8-oxo-7,8-dihydro-9H-purin-9-yl) propyl] (3-morpholin-4-ylpropyl) amino] methyl }phenyl) acetate and their use in therapy (2014-03-18),

14. 8673353 - Tablet having improved elution properties (2014-03-18),

15. 8669270 - SNS-595 and methods of using the same (2014-03-11),

Dainippon Sumitomo Pharma Co., Ltd. is a leading global pharmaceutical company headquartered in Japan. Their mission is to contribute to the health and well-being of people around the world through the creation of innovative and reliable pharmaceutical products. With a diverse portfolio of prescription drugs and over-the-counter medicines, Dainippon Sumitomo Pharma is committed to improving the quality of life for patients and addressing unmet medical needs. They strive to achieve sustainable growth by embracing digital transformation, fostering partnerships, and investing in research and development.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 30 2025

140 Patents

#88 in Osaka

#872 in Japan

#5,642 in the World

Dainippon Sumitomo Pharma Co., Ltd.

Forward Citations = 853

257 inventors:

Yoshiaki Isobe (8 out of 28 patents)

Ayumu Kurimoto (7 out of 9 patents)

Stephen Thom (7 out of 60 patents)

4. Tomohiro Toyoda (6 out of 11 patents)

5. Masashi Gotoh (6 out of 8 patents)

Please report any incorrect information to support@idiyas.com

Loading…